Abcellera Biologics Inc
NASDAQ:ABCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
CA |
|
Paltalk Inc
NASDAQ:PALT
|
US |
|
Blaize Holdings Inc
NASDAQ:BZAI
|
US |
|
E
|
Erlebnis Akademie AG
F:EAD
|
DE |
|
K
|
Kancera AB
F:3EE0
|
SE |
|
C
|
Cerro De Pasco Resources Inc
CNSX:CDPR
|
CA |
|
Turk Tuborg Bira ve Malt Sanayii AS
IST:TBORG.E
|
TR |
|
N
|
Nasmedia Co Ltd
KOSDAQ:089600
|
KR |
|
Sigma Healthcare Ltd
ASX:SIG
|
AU |
|
M
|
Multibax PCL
SET:MBAX
|
TH |
|
B
|
BlackBerry Ltd
NYSE:BB
|
CA |
Wall Street
Price Targets
ABCL Price Targets Summary
Abcellera Biologics Inc
According to Wall Street analysts, the average 1-year price target for
ABCL
is 9.35 USD
with a low forecast of 7.07 USD and a high forecast of 12.6 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ABCL's stock price target?
Price Target
9.35
USD
According to Wall Street analysts, the average 1-year price target for
ABCL
is 9.35 USD
with a low forecast of 7.07 USD and a high forecast of 12.6 USD.
What is Abcellera Biologics Inc's Revenue forecast?
Projected CAGR
-22%
For the last 6 years the
compound annual growth rate for
Abcellera Biologics Inc's revenue is
37%.
The projected
CAGR
for the next 3 years is
-22%.
